d DST Investment Properties: KB Diversified Health Care DST 21 | Kingsbarn Realty Capital
KB Diversified Healthcare DST 21 — Medical Clinic Portfolio (4-Properties)

KB Exchange Trust is pleased to offer this high-quality, credit-tenant real estate investment that is structured as a Delaware Statutory Trust to suit 1031 exchange investors. This Offering consists of four properties totaling approximately 33,200 square feet of medical clinic space. Two of the properties have leases guaranteed by Fresenius Medical Care Holdings, a subsidiary of Fresenius Medical Care (“FMC”). FMC is rated as investment-grade by Standard & Poor’s. The two remaining properties have leases guaranteed by Davita Inc., a U.S. Fortune 500 company in 2017. Combined, Fresenius and Davita account for 70% of the dialysis market in the United States.* The four properties are located in Colorado, Texas, and Missouri (2).

Investors shall receive an initial annual cash flow of 6.00% which will be distributed monthly by the asset manager, Emerson. Emerson Asset Management, a national, third-party, property and asset management company shall make all distributions to investors and will provide monthly operating statements for the properties. The Delaware Statutory Trust ownership structure is ideal for passive investors and makes this investment "like-kind" for purposes of a 1031 exchange.

Download Investment Summary
Full Name:
E-mail Address:
Phone Number:
Are You In An Exchange?:
Home Kingsbarn Realty Capital
DST Net-Lease Properties
DST Multifamily Net-Lease
Recent Transactions
DST 101
1031 Exchange
Document Vault

About Fresenius Medical Care

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis due to chronic kidney failure. Fresenius is a $25 billion worldwide company with over 105,000 employees and a network of 3,500 dialysis clinics in North America, Europe, Latin America, Asia-Pacific, and Africa.

About DaVita Dialysis

DaVita Healthcare Partners, Inc. ("DaVita") (NYSE: DVA) is a leading provider of kidney care in the United States and is the guarantor of the lease. DaVita is traded on the New York Stock Exchange (NYSE: DVA) and boasts a market cap in excess of $15 billion. Between May 2006 and May 2016, DVA shares increased 210% from $24.50/share to $77/share. Comparatively, the Dow Jones Average only increased 59% during the same time period. Founded in 1998, DaVita operates more than 2,100 dialysis clinics, serves more than 170,000 patients annually and has approximately 60,000 employees.


› Equity Offering: $7,400,000

› Minimum Investment: $100,000

› Initial Cash Flow: 6.00%

› Loan-To-Cost: 52.78%


› Long-Term Leases (14 - 15 Years)

› Cost Segregation Studies for Accelerated Depreciation

› Fresenius is Publicly-Traded (NYSE: FMS)

› DaVita Dialysis is Publicly Traded (NYSE: DVA)

› Flexible Equity Investments

› DST Structure Ideal for 1031 Exchanges

Call Us To Discuss This Investment Opportunity: 424.343.9000
Jeff Farnsworth
Regional VP,
San Francisco
Steven Prescott
Regional VP,
San Diego
Ron Glasgow
Regional VP,
Los Angeles
Mat Wilkins
Regional VP, 
Orange County

This website does not offer to sell, or a solicitation of an offer to buy, securities. Offers can only be made through the Private Placement Memorandum which contains various and important risk disclosures. This web site does not purport to be complete and should be viewed in conjunction with the Private Placement Memorandum. An investment of this sort is speculative and involves a high degree of risk. Projections of future performance contained herein are based on specific assumptions discussed more fully in the Private Placement Memorandum and do not constitute a guaranty of future performance.

DST Interests in any of the properties displayed on this website may be sold only to "accredited investors," as defined in Regulation D under the U.S. Securities Act of 1933, as amended (the "Securities Act"), which, for natural persons, refers to investors who meet certain minimum annual income or net worth thresholds. Offers and sales of DST interests have not and will not be registered under the Securities Act or the laws of any U.S. state or non-U.S. jurisdiction and may be offered only pursuant to an exemption from such registration. Neither the U.S. Securities and Exchange Commission nor any other regulatory authority has passed upon the merits of an investment in the DST Interests, has approved or disapproved of DST Interests or passed upon the accuracy or adequacy of this website and any supplementary materials describing the DST Interests. DST Interests are also not subject to the protections of the Investment Company Act of 1940, including the limitations on self-dealing, affiliated transactions and leverage contained therein. DST Interests are subject to legal restrictions on transfer and resale in accordance with the governing documents of the Trust and applicable securities laws, and investors may be unable to sell or transfer their DST interests. In addition, there is no public market for the DST interests and no such market is expected to develop in the future. Investing in the DST securities involves risk, and investors should be able to bear the loss of their investment.